TELA Bio Q2 2024 revenue $16.1M (+11% YoY), net loss $12.6M; reiterates FY guidance

TELA Bio, Inc.

2024-Q2 EPS reported -$0.74 revenue$32,694,000

Revenue $16.1M, +11% YoY; net loss $12.6M vs $10.8M loss in Q2 2023.
FY 2024 revenue guidance reiterated at $74.5M-$76.5M (27%-31% YoY growth).
Appointed Greg Firestone as CCO on May 20 to boost commercial productivity.
Launched robotically compatible OviTex IHR for inguinal hernia market in U.S.
Expects $3M-$7M in total NIVIS revenue share payments over next eight quarters starting Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.